INVO Fertility Resolves Nasdaq Delisting Threat, Consolidates Alabama Joint Venture
IVF is trading near its 52-week low of $1.2 (0.0% above the low) on light trading volume (0.3× avg).
Summary
INVO Fertility announced it has resolved its Nasdaq timely filing non-compliance, removing an immediate delisting threat, and has acquired its joint venture partner for the Alabama fertility clinic.
Key Events · Corporate Governance and Compliance · IVF
-
Nasdaq Delisting Threat Resolved
The company received notification from Nasdaq that it is now compliant with the Timely Filing Rule, closing the matter of previous non-compliance regarding its 10-K and 10-Q filings. This removes a significant overhang and potential delisting risk.
-
Acquisition of Joint Venture Partner
INVO Centers, a wholly-owned subsidiary, acquired 100% of HRCFG, LLC, its joint venture partner for the Birmingham, Alabama fertility clinic, for $175,001. This consolidates one of the company's four existing clinics into its financial statements.
Analysis · IVF · Industrial Applications And Services
This filing brings crucial positive news for INVO Fertility, which has been grappling with significant financial distress, including a 'going concern' warning and multiple Nasdaq non-compliance notices. The resolution of the Nasdaq timely filing issue removes an immediate delisting threat, providing a much-needed reprieve and stability for the company's stock. Additionally, the acquisition of its joint venture partner for the Alabama clinic, while small in monetary value, simplifies the company's structure by consolidating an existing operation into its financial statements.
At the time of this filing, IVF was trading at $1.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.20 to $183.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.